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Abstract 
Peptidyl prolyl isomerases (PPIases) are proteins belonging to the immunophilin family and 
are characterised by their cis-trans isomerization activity at the X-Pro peptide bond, in addition 
to their tetratricopeptide repeat (TPR) domain, important for interaction with the molecular 
chaperone, Hsp90. Due to this unique structure these proteins are able to facilitate protein-
protein interactions which can impact significantly on a range of cellular processes such as cell 
signalling, differentiation, cell cycle progression, metabolic activity and apoptosis. 
Malfunction and/or dysregulation of most members of this class of proteins promotes cellular 
damage and tissue/organ failure, predisposing to ageing and age-related diseases. Many 
individual genes within the PPIase family are associated with several age-related diseases 
including cardiovascular diseases (CVDs), atherosclerosis, type II diabetes (T2D), chronic 
kidney disease (CDK), neurodegeneration, cancer and age-related macular degeneration 
(AMD), in addition to the ageing process itself. This review will focus on the different roles of 
PPIases, and their therapeutic/biomarker potential in these age-related vascular diseases. 
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Introduction 
With an increase in life expectancy, the biggest challenge facing healthcare organisations is the 
management of age-related diseases. Age is the most strongly associated risk factor for diseases 
such as CVDs, cancer, T2D, CKD, neurodegenerative diseases, AMD and atherosclerosis1. 
Therefore finding a way of slowing down aging and delaying or preventing these age-related 
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diseases will lead to longer life expectancy, healthy aging, and a better quality of life, thus 
reducing the financial burden on healthcare systems. 
 
Twin studies have shown that for cohorts born about 100 years ago, approximately 25% of the 
variation in population lifespan is determined by genetic differences and that the genetic 
influence on lifespan and age-related diseases in particular, becomes relevant in those people 
who survive to 60 years2. There have been major successes in the identification of new genetic 
variants involved in important age-related disorders including: cancer (in particular, prostate, 
breast and colon3–5; CVDs6,7 and CKD8. However, many of these genetic variants, individually 
or combined, explain only a small component of the heritability of each disease. This modest 
contribution does not match with the high recurrence risks of age-related disorders in families. 
This apparent paradox may in part be explained by the contribution of low frequency variants, 
unrecognized single nucleotide polymorphism (SNP) epistasis, gene-environment interactions 
and epigenetic and gene expression changes. Epigenetic data is particularly valuable to help 
interpret genome wide association studies (GWAS) by adding biological/mechanistic 
information9,10. One of the major challenges over the next few decades will be to unravel the 
interactions between genetic variants and environmental factors. GWAS have shown that SNPs 
linked to multiple diseases are generally clustered on chromosome 6, in particular the Major 
Histocompatibility (MHC) locus within 6p21, in addition to the INK4/ARF (CDKN2a/b) 
tumour suppressor locus on chromosome 9p21.3. These SNPs accounted for almost a third of 
all the diseases analysed by GWAS11.  
 
Aberrantly activated pathways in aging identified by association studies using long-lived 
cohorts include the insulin/insulin growth factor-1 (IGF-1), antioxidant, inflammatory, sirtuin, 
lipid metabolism, stress resistance and the mammalian target of rapamycin (mTOR) 
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pathways12–18. The main targets of the insulin and IGF-1 pathway are the FOXO transcription 
factors which have important roles in stress resistance, immunity and metabolism19,20. The 
sirtuin and mTOR pathways are nutrient-sensing pathways and these pathways are linked to 
longevity (high sirtuin and low mTOR levels) because of their ability to mediate the effects of 
nutrients and insulin. Since the mTOR pathway is a strongly implicated pathway, it represents 
a viable target for prevention of aging and age-related disease. Peptidyl prolyl isomerases 
(PPIases) also known as immunophillins, are a family of proteins that bind to rapamycin-
mTOR complexes and regulate the mTOR signaling pathway. These proteins therefore play a 
significant role in aging and age-related diseases21. Therefore, the focus of this review will be 
on the role of PPIase in aging and age-related diseases: CVDs, T2D, CKD, ND, AMD and 
cancer. 
PPIases  
The PPIase family are important determinants of ageing and disease. Many individual genes 
within the PPIase family are associated with several age-related diseases, in addition to the 
ageing process itself. Peptidyl prolyl isomerases (PPIases) are proteins belonging to the 
immunophilin family and are characterised by their cis-trans isomerization activity at the X-
Pro peptide bond. The term immunophilin is derived from the ability of these proteins to bind 
immunosupressive drugs; cyclophilins (18 members, 17 genes) bind to cyclosporine A and 
FKBPs (FK506 binding proteins; 17 members, 17 genes) bind to the macrolide, FK506. A third 
subfamily, parvulins (3 members, 2 genes), contain the PPIase domain but do not bind 
immunosuppressive drugs22. Immunosuppression is generally associated with the smaller 
PPIase-complexes and the larger PPIases lack this effect but they contain the tetratricopeptide 
repeat (TPR) domain facilitating protein-protein interactions, significantly impacting many 
essential cellular processes. Therefore, aberrant function of these proteins can lead to tissue 
damage and predisposition to aging and age-related disease 23,24. 
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Aging  
Aging, in terms of endothelial system changes, encompasses molecular and functional 
modifications such as shortening of telomeres, structurally and functionally altered endothelial 
cells, increased levels of vasoconstrictive, pro-inflammatory, proliferative and pro-coagulatory 
substances, reduced nitric oxide (NO) bioactivity and apoptosis25. These processes lead to an 
increase in blood pressure, a reduction in the glomerular filtration rate, atherosclerosis and 
therefore to age-related diseases. 
 
More recently, cellular senescence and changes in immune system surveillance have been 
identified as being the most significant processes in aging due to their ability to activate pro-
inflammatory pathways26–28. Other aberrant aging processes include protein aggregation, DNA 
damage, mitochondrial damage and accumulation of reactive oxygen species (ROS; Figure 1). 
More recently, research has focused on the role of aging stem cells on age-related diseases and 
the aging process itself. Due to their long lifespan, stem cells are more prone to cellular damage 
as they accumulate ROS, damaged proteins, DNA damage, epigenetic alterations and 
mitochondrial dysfunction29. All of these aberrant changes can lead to stem cell apoptosis, 
senescence, dysfunction and thus the inability of stem cells to orchestrate tissue regeneration 
and proliferation.  
 
The role of PPIases in aging 
The role of many individual PPIases in ageing has been studied. PPIases play a significant role 
by binding to and regulating the mTOR signalling pathway which has very well characterised 
roles in ageing and age-related diseases21. Furthermore, other PPIases such as CypA expression 
increases with ageing30–32 and suppression of CypB induces cellular senescence33 and its 
6 
 
expression decreases in ageing rats34. Likewise, CypC35,36; CypD37–39; CypJ40 have all 
demonstrated significant roles in animal models of ageing. FKBPL, a divergent member of the 
FKBP group of immunophilins, resides on the gene loci, 6p21.3 which is within a significant 
peak of age-related disease association11. Furthermore, it controls the levels of Sirt1 
(unpublished data from our lab), a direct regulator of aging41. Importantly, Pin1 has the 
strongest link to ageing and is indeed a critical regulator of aging; Pin1-/- mice develop 
normally but show pronounced and premature aging, with reduced body size and bone density 
as well as atrophy of the skin, testis and breast42. Pin1 appears to control ageing by telomere 
shortening, via TRF1 phosphorylation and stability43, and also regulates senescence, via the 
p53-BTG2 pathway44. 
 
Cardiovascular diseases 
CVDs are the most common of all age-related diseases and are the leading cause of death in 
people over the age of sixty five45. Because the aging process leads to an overproduction of 
pro-inflammatory, pro-coagulatory, vasoconstrictive and other related factors, it can lead to 
brittle heart walls, leaky/thickened heart valves and deterioration in the heart muscle, leading 
to poorer ability to pump blood efficiently around the body46. Therefore, these changes together 
with the age-related changes in the endothelial system mentioned above, can lead to 
atherosclerosis, angina, atrial fibrillation and orthotropic hypertension, potentially causing 
myocardial infarction and stroke47. The key signalling pathways associated with CVDs include 
the insulin and IGF-1, sirtuin and mTOR pathways. The IGF-1 pathway appears to have a 
protective mechanism against atherosclerosis in humans whereas in mice it led to an increase 
in life span48,49. The role of the sirtuin pathway in CVD is unclear due to a lack of consistency 
in the published data to suggest a strong role for this pathway in the development of CVDs; 
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further research is therefore required50. On the other hand, the inhibition of the mTOR pathway, 
has demonstrated a role in longevity51; rapamycin can alleviate cardiac hypertrophy, T2D, 
adipogenesis and lipogenesis as such has a vital role in aging and CVDs47,52. Furthermore, the 
AMPK (AMP-protein activated kinase) signalling pathway, which negatively regulates mTOR, 
is also involved in CVDs; aberrant expression of AMPK in simple organisms, mice and humans 
has been implicated CVDs and aging53–55. 
 
The role of PPIases in CVDs 
FKBP12, a cytoplasmic FKBP, has a well-established interaction with the ryanodine receptor, 
RyRs, resulting in stabilisation of this channel. FKBP12 knockdown results in the opening of 
the RyRs channel and augments calcium release into a wide range of tissues56,57. Therefore, 
FKBP12 and FKBP12.6 have an important role in cardiac regulation and deficiency of these 
proteins contributes to the pathogenesis of hypertension. In murine models, FKBP12 knockout 
(KO) resulted in cardiac defects and altered ryanodine receptor function58–61. Therefore the 
treatment with FK506 and rapamycin may contribute to vascular dysfunction and hypertension 
by induced intracellular leakage of calcium ions in endothelial cells56,62. A novel antiarrhythmic 
compound, K201 (JTV– 519), which binds to FKBP12.6, thus stabilising RyRs channels and 
decreasing spontaneous calcium release, is currently in clinical trials63.  
 
The most abundant member of the cyclophilin family, CypA, is excreted exogenously in 
response to inflammatory stimuli and able to increase ROS formation in endothelial cells, 
macrophages and vascular smooth muscle cells64–67. Therefore, CypA is a critical regulator of 
CVDs. In terms of vascular remodeling, CypA KO mice had significantly less thickened 
arteries when compared to the wild type (WT) mice and therefore are less likely to developed 
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cardiac/vascular hypertrophy or myocardial ischaemia which can lead to myocardial injury68–
70. CypA’s involvement in ROS generation and cardiac fibroblast proliferation and migration, 
renders it responsible for the development of cardiac hypertrophy, the basis of most of the 
CVDs70,71. Interestingly serum levels of CypA were significantly higher in patients with acute 
coronary syndrome (ACS) when compared to healthy patients or patients with stable angina 
and the levels also correlated with the severity of ACS, potentially suggesting a role for CypA 
as a biomarker to predict the severity of ACS72. Furthermore, CypA has a well-established role 
in atherosclerosis and the mechanisms involve an increase in the uptake of low-density 
lipoproteins by the vessel wall due to CypA-mediated overexpression of the scavenger 
receptors, pro-inflammatory and endothelial cell activation of vascular cell adhesion molecule-
1 (VCAM-1) and a decrease of the endothelial nitric oxide synthase32  
Another cyclophilin with a role in CVDs is CypD. Interestingly, it has a cytoprotective role 
during ischaemia-reperfusion injury as a regulator of the mitochondrial permeability transition 
pore (mPTP) complex formation73,74. 
 
Finally, Pin1, the most extensively researched member of the parvulins subgroup (Pin1-3), has 
a significant role in cardiac hypertrophy. The loss of Pin1 attenuates cardiac hypertrophic 
responses following severe vasoconstriction by binding to Akt, mitogen activated protein 
kinase (MEK) and Raf-1; all essential components of the cardiac hypertrophy75. 
 
Type II diabetes 
T2D is an age-associated disease, more specifically related to accelerated aging. Most T2D 
patients are between the age of 65 and 7476. T2D is more prevalent in men within this age group 
and its incidence decreases above 75 years of age77. The pathophysiology of T2D is very 
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closely linked to the dysfunction of pancreatic islet β-cells in addition to insulin resistance78. 
The pancreatic β-cells appear to lose their proliferative, secretory and regenerative function as 
part of aging, mainly due to cellular senescence79. Furthermore, the proliferative and apoptotic 
ability of the pancreatic β-cells seem to be the most apparent change in aging, obese and 
diabetic patients. These cells are also able to adjust their proliferative activity in metabolic 
distress e.g. in metabolic syndrome, by increasing their self-renewal capacity to manage the 
increasing demand for glucose utilisation79. Interestingly, the pancreatic β-cells display similar 
characteristics to stem cells such as low proliferative profile and a very long lifespan80. The 
proliferative and regenerative capacity of β-cells might be diminished with age as a result of 
accumulation of DNA damage during their long lifespan or it could be that these cells undergo 
senescence or apoptosis as a result of age-mediated shortening of the telomeres and/or 
activation of p53 and/or p16INK4A 81,82. 
 
Aberrant molecular mechanisms involved in the induction of cellular senescence of the 
pancreatic β-cells include telomere shortening, cycle-dependent kinase inhibition by p53 and 
p16INK4A, which are also tumour suppressor genes83. Other pathways involved in the 
dysfunction of the pancreatic β-cells include the mTOR, sirtuin and IGF-1 pathways, also 
strongly associated with aging and other age-related diseases84. Furthermore, the negative 
regulator of the mTOR pathway, AMPK, has also been significantly implicated in the 
metabolic disorders and T2D; aberrant expression of AMPK in both mice and humans leads to 
insulin resistance54. 
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The role of PPIases in T2D 
The role of PPIases in T2D is still in its infancy however some interesting data has been 
recently reported to suggest important role for this group of proteins in T2D. For example, 
FKBP51 SNPs were found to be associated with T2D phenotypes in large population studies 
85. Also, the change in FKBP51 gene expression was demonstrated in response to stress and 
diet therefore indicating a correlation between FKBP51 levels and higher food intake. 
Similarly, in mice, FKBP51 KO demonstrated a leaner phenotype when compared to the WT 
mice86. Furthermore, in conjunction with insulin resistance markers, FKBP51, as a steroid 
hormone responsive and regulatory gene, demonstrated an increase in the expression, following 
dexamethasone exposure85.  
 
Moreover, CypA has a role in T2D and vascular complications of T2D due to its pro-
inflammatory role; patients with T2D were reported to have lower levels of CypA in high 
glucose-primed monocytes but high plasma levels of CypA when compared to healthy 
volunteers therefore suggesting a role for CypA as a biomarker of inflammation in T2D 
patients87. Moreover the role of the PPIase, FKBPL, in the regulation of vascular/angiogenic 
functions implicates their potential in T2D-mediated vascular abnormalities (Yakkundi et al, 
unpublished data). 
 
Chronic Kidney Disease  
CKD is a leading cause of morbidity and mortality. Epidemiological studies demonstrated 
around 13% prevalence worldwide88,89. CKD arises from complete progressive destruction of 
nephrons resulting in the intact nephrons having to manage an increased load8,90. Despite 
research efforts, the pathophysiology of CKD is still not fully understood, although vascular, 
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glomerular and tubular events are implicated in the disease91,92. Furthermore, podocytes or 
visceral epithelial cells within the Bowman’s capsule have a role in preventing protein escape 
into the urine and therefore the loss of podocytes has been associated with the development of 
diabetic neuropathy93,94. Aberrant mTOR activation is associated with this process and its 
inhibition by drugs such as rapamycin may be of a potential clinical benefit93,95. Similarly, the 
mTOR pathway is involved in aldosterone mediated signalling through the mineralocorticoid 
receptor within renal tubular epithelial cells of distal nephrons; important for the regulation of 
fluid homeostasis96,97. The activation of the mineralocorticoid receptor and its target genes 
including some of the PPIases, has been linked to tissue inflammation and fibrosis leading to 
CKD98–100. 
The role of PPIases in CKD 
In relation to CKD, FKBP12 exhibits an inhibitory activity on calcium oxylate crystal 
deposition and may prevent nephrolithiasis101. Nephrolithiasis is often perceived as a relatively 
minor acute illness, but increasing evidence suggests that it can lead to CKD102–104. 
Furthermore, the pathogenesis of the condition shares overlapping features of many diseases 
of ageing such as hypertension, CVD and diabetes mellitus103,105,106. Recently, using a GWAS 
population analysis approach, FKBP51 has shown significant differences in DNA methylation 
in CKD patients107. Aldosterone plays a significant role in the development of CKD and 
evidence suggests that FKBP51 protein and mRNA expression are induced by aldosterone in 
the kidney and intestinal tissues108–110. On the other hand, CypA has a role in renal acidosis111, 
diabetic nephropathy112 and renal cell carcinoma113. Furthermore, Pin1 inhibition affects CKD 
associated with secondary parathyroidism114. 
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Neurodegeneration 
Neurodegeneration is the umbrella term for the progressive failure of neuronal networks 
leading to neuron death; many of these diseases share similarities at the sub-cellular level 115,116. 
Ageing is the main risk factor for development of these diseases and the accumulation of 
atypical proteins, abnormal tangles and network dysfunction are classic hallmarks of these 
diseases117.  
 
Protein aggregation is a well-known feature of these diseases; however, the role of this process 
is not fully understood. Post-mortem examination of deceased brains have revealed that 
amyloid plaques in Alzheimer’s disease and Lewy bodies in Parkinson’s disease can be present 
even in asymptomatic patients and the extent of plaques present does not correlate to the 
severity of the disease at the time of death118.  
 
Sustained activation of neuronal PI3K/Akt/mTOR signalling has been noted in early 
Alzheimer’s disease119. In the temporal lobes of Alzheimer’s patients, Akt activation leads to 
mTOR and tau phosphorylation and a decrease in cyclin-dependent kinase inhibitor 1120. 
Furthermore, the aberrant activation of the Akt pathway has been linked to disrupted clearance 
of Aβ and tau resulting in synaptic loss and cognitive decline119. Nevertheless, the cause of 
Alzheimer’s disease is still largely unknown however the most prevalent genetic risk factor is 
the presence of ε4 allele of the apolipoprotein E (APOE) and it is expressed in half of sporadic 
Alzheimer’s disease cases121,122.  
 
On the other hand, Parkinson’s disease is the second most common neurodegenerative disease 
after Alzheimer’s diseases. It is a degenerative disorder resulting from the death of the 
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dopamine producing cells in the substantia nigra (SN)123–125. Age-related mitochondrial 
dysfunction and alterations in protein degradation are more detrimental to the neurons in the 
SN than in any other regions of the brain126. The classic hallmark of this disease is the presence 
of the protein alpha synuclein which binds to ubiquitin in damaged cells forming oesinophilic 
cytoplasmic inclusions called Lewy bodies124,125,127. In Parkinson’s disease, the 
PI3K/Akt/mTOR pathway is dysregulated in a different manner than in Alzheimer’s disease. 
The dopaminergic neurons from Parkinson’s patients display downregulation of 
phosphorylated Akt and supressed mTOR signalling resulting in neuronal death128. 
Furthermore, rapamycin, the inhibitor of mTOR, has a neuroprotective effect by protecting 
phosphorylated Akt at a critical site for cell survival129. 
 
The role of PPIases in neurodegeneration 
Calcium dysregulation contributes to unhealthy brain aging by reducing neural excitability and 
impairing memory. Disruption of FKBP12 in the hippocampal neurons destabilised calcium 
and in vivo FKBP12 knockdown is associated with an upregulation of RyR2 and mTOR protein 
expression130. FKBP12 has been shown to bind to the intracellular domain of the amyloid 
precursor pathway and shift APP processing to the amyloidogenic pathway 131,132. Moreover, 
the FKBP12 gene expression is downregulated in the hippocampus of aging rats and in early 
stage Alzheimer’s patients133. When FK506 is used as an immunosuppressant agent, it appears 
to have neuroprotective effects134.  
 
FKBP38 is a well-known inhibitor of apoptosis through a reduction in mitochondrial Bcl-2 
135,136. Hsp90 can inhibit the apoptotic function of FKBP38 by interfering with the 
FKBP38/calmodulin/calcium complex which regulates the anti-apoptotic protein, Bcl-2137. 
14 
 
This property of FKBP38 protein has been exploited for the treatment of neurodegenerative 
diseases136,138.  
 
FKBP51’s PPIase activity has a role in microtubule stabilisation through Hsp90-mediated 
dephoshorylation of tau139,140. On the other hand, FKBP52 is ubiquitously expressed at high 
levels and has been associated with microtubule destabilisation and tubulin depolymerisation 
140–142. FKBP51/FKBP52 bound to heat shock proteins may have a role in neurodegeneration 
by modulating protein folding and aggregation23. FKBP51 siRNA knockdown reduced tau 
levels in HeLa cells and FKBP51 overexpression increased levels of tau139. In addition, 
knockdown of Hsp90 also reduced levels143. In contrast, FKBP52 overexpression 
downregulated tau protein levels and knockdown resulted in increased tau binding to 
microtubules, resulting in longer projections131,142. Cao and Konsolaki proposed that the 
opposing effects of FKBP51 and FKBP52 could be due to the differences in PPIase activity as 
tau contains a high percentage of proline residues131. Furthermore, FKBP52 is upregulated after 
injury in regenerating neurons and Alzheimer’s patients have a lower expression of FKBP52 
in the temporal lobe and hippocampus131. FKBP52 is involved in the regulation of intracellular 
copper and this may cause FKBP52 to have an effect on Aβ levels144–146. Furthermore, 
Conejero-Goldberg and colleagues demonstrated that FKBPL was one of the key genes 
differentially expressed in the brain tissue, where it appeared to act in a protective role, in 
young individuals at high risk of Alzheimers disease preselected by the APO4 signature147.  
 
The role of CypA in Alzheimer’s disease has also been reported, possibly due to its ability to 
activate pro-inflammatory pathways, NF-ĸB and MMP-9; these pathways in brain capillary 
pericytes regulate the release of neurotoxins. This whole process is initiated by APO4 within 
astrocytes148. CypD’s involvement in the mPTP complex has also found application in 
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Alzheimer’s disease due to recent reports which suggest that Aβ proteins influence mPTP 
formation when in a complex with CypD149. Conversely, the loss of Pin1 expression is 
correlated with Alzheimer’s disease and neurodegeneration due to Pin1’s important role in the 
stabilisation and regulation of tau and Aβ proteins42. Tau protein hyperphosphorylates in the 
absence of Pin1 leading to its dysfunction and inability to regulate microtubule stabilisation in 
the neurons150. 
 
Age-related macular degeneration 
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide and old 
age is the major risk factor with an incidence of 10% in individuals over 80 years of age151,152. 
It results from degeneration of the macular region of the retina, a central part of the retina and 
AMD susceptibility is increased by age, environmental (e.g. smoking) and genetic factors152,153. 
Many different genetic factors have been implicated in AMD including SNPs within some of 
the proteins involved in the mTOR pathway154. 
 
The role of PPIases in AMD 
In AMD GWAS the presence of SNPs on chromosome p6.21 in the FKBPL region was 
demonstrated therefore suggesting a potential role for FKBPL as an AMD susceptible gene155. 
This study was carried out using two cohorts of advanced AMD patients against matched 
controls to validate the findings and it also indicated Notch4 as a potential AMD susceptible 
gene. Our own lab has generated data to suggest that in addition to the well-established 
FKBPL’s regulatory role of the CD44 pathway, it is also involved in the regulation of the Notch 
pathway (unpublished data). 
Cancer 
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Cancer is defined as the development of ‘abnormal cells’ due to genetic and epigenetic changes 
in oncogenes and tumour suppressors156. These genetic changes can be inherited, acquired by 
various DNA damaging agents or certain types of viruses. There are a few theories of 
carcinogenesis nevertheless it is considered a multistep process involving genetic instabilities 
which drive normal cells to malignant, cancer cells. More recently, a subgroup of cancer cells, 
termed cancer stem cells (CSCs) or tumour initiating cells, have been characterised as a group 
of cells carrying the oncogenic and tumour suppressor mutated genes responsible for tumour 
initiation and progression157. 
Numerous cellular and intracellular pathways regulating tumourigenesis have been implicated 
in the development of cancer. A pathway readily activated as a result of a loss of the main 
tumour suppressor genes, p53 or PTEN, is PI3K-Akt survival pathway158. This pathway 
regulates the mTOR pathway and once the mTOR pathway is activated, negative feedback 
results in PI3K inhibition. Therefore when the mTOR pathway is inhibited by rapamycin, for 
example, the mutated or lost negative feedback loops, commonly present within cancer cells, 
activate the PI3K-Akt pathway instead of inhibiting it, thereby preventing the anti-proliferative 
effect of the mTOR pathway inhibition159,160. 
 
The role of PPIases in cancer 
The roles of PPIases in cancer have been studied extensively. Some members appear to have 
oncogenic activity whilst others behave as tumour suppressors. FKBP12 is overexpressed in 
benign and malignant endothelial-lined vasculature and as a natural ligand of TGF-β receptor 
I is subsequently involved in regulating cancer invasion161. Knockdown of FKBP12 results in 
the cell cycle arrest at the G1 phase by downregulation of TGF-β signalling162. Furthermore, 
FKBP12 activates TGF-β receptor I kinase thus triggering apoptosis by a mitochondrial 
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dependent pathway163. In addition, it is a regulator of H-Ras trafficking by promoting 
depalmitoylation through its PPIase activity164. Disruption of the interaction between FKBP12 
and calcineurin signalling leads to potent anti-angiogenic effects and tumour growth inhibition 
in breast cancer165.  
 
FKBP38 is capable of potentiating the biological function of Bcl-2 protein leading to 
tumourigenesis and chemoresistance136,166. Furthermore, Bcl–2 overexpression has been 
associated with the cancer stem cell phenotype and it may contribute to chemoresistance within 
these cells167. 
 
FKBP51 expression is hormone related and its overexpression has been associated with 
leukaemia, breast, prostate and brain tumours168,169. FKBP51 is a negative regulator of the Akt 
pathway and regulates cell response to chemotherapy170. Furthermore, FKBP51 regulates the 
NF-ĸB pathway which is implicated in apoptosis and radioresistance in melanoma cells171,172. 
More recently, the role of FKBP51 in stemness and metastasis in melanoma was demonstrated 
by Romano et al (2013), where FKBP51 was overexpressed and associated with tumour 
aggressiveness and treatment resistance by stimulation of the EMT process, migration and 
invasion via the TGF-β pathway173. Furthermore, androgens upregulate FKBP51 by initiating 
direct binding between FKBP51 and the androgen receptor (AR)174. In murine xenograft 
models it was demonstrated that FKBP51 is a direct regulator of cell growth and may have a 
role in the highly invasive androgen-independent type of prostate cancer174,175. The 
FKBP51/AR interaction is mediated by Hsp90, and Hsp90 inhibitors such as geldanamycin are 
currently in clinical trials in a variety of cancers176,177. In pancreatic cancer, FKBP51 acts as a 
scaffolding protein to the phosphatase PHLPP resulting in upregulation of the pro-survival Akt 
pathway and reducing sensitivity to the chemotherapy170. Conversely, in colorectal 
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adenocarcinoma, FKBP51 suppresses proliferation through its action on the glucocorticoid 
receptor178. 
 
Less is known about the role of FKBP52 in cancer, although its inhibition has been shown to 
block androgen receptor dependent gene expression and prostate cancer cell proliferation179. 
Moreover, FKBP52 is highly expressed in hormone-positive cancers such as oestrogen receptor 
positive (ER+) breast cancer; its expression in pre-invasive breast cancer was also much higher 
than the surrounding normal breast tissue speculating its role in breast cancer initiation180,181. 
FKBP52 is not a functional regulator of the oestrogen receptor but interestingly, it is 
upregulated in breast tumours and FKBP52 gene methylation only occurs in ER negative breast 
cancer cells182. Furthermore, FKBP52 auto-antibodies may be a useful biomarker for early 
diagnosis and monitoring of breast cancer183. 
 
FKBP65 is highly expressed in early benign lesions in the colon, compared to normal 
mucosa184. This suggests that FKBP65 may be involved in colorectal carcinogenesis and could 
be a novel colorectal biomarker183. FKBP65 is strongly expressed in normal and benign ovarian 
epithelium but a low expression in high grade serous carcinoma (HGSC) is probably due to 
frequent loss of chromosome 17 in HGSC185,186. This indicates a tumour suppressor function 
for FKBP65 in ovarian carcinomas.  
 
FKBPL has a well-established role in cancer and whilst most FKBPs are positive regulators of 
cancer growth, FKBPL, as a divergent member of this family, is not. FKBPL acts as a co-
chaperone protein in a complex with Hsp90 where it has a regulatory role in steroid receptor 
signalling (ER)187; (AR)188;  (GR)189. Due to this negative regulatory effect of the steroid 
receptors, overexpression of FKBPL demonstrated inhibition of cancer cell growth in ER+ 
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breast cancers187; in lymphoma this inhibitory effect was associated with a FKBPL, Hsp90 and 
p21 complex190. Furthermore, in ER+ breast cancer, high FKBPL levels improved the response 
to endocrine therapy such as tamoxifen and fulvestrant and sensitised cells to oestrogen 
deprivation and was also prognostic for survival187. Other relevant roles of endogenous FKBPL 
in a complex with Hsp90, p21 and GTSE-1 (G2 and S phase expressed protein 1) include, 
chemo- and radiosensitivity via regulation of the cell cycle protein, p21CIP1/WAF1, and a 
reduction in the DNA repair191,192. All of these FKBPL-related roles are associated with 
intracellular FKBPL however more recently, an extracellular role for FKBPL was identified. 
This extracellular role was associated with a potent anti-angiogenic and anti-CSC function 
which is initiated following binding of FKBPL to the CD44 cell surface receptor193–195. The 
region responsible for this interaction is the N-terminal region of FKBPL, which is unique and 
not homologous to other FKBPs. Based on this anti-angiogenic domain, a clinical candidate 
23-amino acid therapeutic peptide, ALM201, was designed in collaboration with Almac 
Discovery which will enter clinical trials this year196. Therefore, FKBPL as a divergent member 
of the FKBPs appears to be involved in similar biological processes in cancer to other FKBPs 
whilst exerting an opposite function as an anti-cancer or tumour suppressor protein.  
 
In cancer CypA is significantly upregulated and as such is involved in malignant 
transformation, tumour growth, invasion, metastasis and the inhibition of apoptosis197–200. This 
is not surprising considering CypA has a role in the stimulation of endothelial cell migration 
which is important for tumour growth and invasion69. Furthermore, CypA is transcriptionally 
regulated by p53 and hypoxia inducible factor-1α (HIF-1α) both factors commonly mutated in 
cancer201. CypA seems also responsible for paclitaxel-induced resistance in endometrial cancer 
and overexpression of CypA can reduce cisplatin and hypoxia-induced apoptosis202,203. On the 
other hand, CypA has also an important role in the cytokinesis where it relocalises from its 
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original position, in the centrosome, to the midbody; the loss of CypD leads to defective 
cytokinesis which can increase genomic instability associated with cancer204. Other members 
of the Cyp family group CypB, CypC and CypD in addition to CypA also appear to be 
upregulated at the transcriptional levels in various cancers201. CypB and CypC are associated 
with the ER and as such form various complexes with other oestrogen-related chaperones and 
CypB, in particular, protects cells from oestrogen receptor stress-induced death205,206. 
However, overexpression of CypB has been linked to tumour progression because it regulated 
various hormone receptors and their downstream targets207. Also, CypB could be a useful target 
for delivery of anti-cancer vaccines due to its two antigenic epitopes identifiable by the 
cytotoxic T-lymphocytes208. Moreover, Cyp40 mRNA levels were reported to be high in 
response to stress in breast and prostate cancer cell lines when compared to normal breast and 
prostate cell lines209. CypD, as mentioned above, is involved in mPTP complex formation and 
as such has a role in the resistance to mPTP-induced cancer cell death. This is mediated by 
other co-chaperone proteins such as Hsp90, TRAP and Hsp60 highly expressed in cancer cell 
mitochondria and their ability to inhibit CypD therefore disabling mPTP formation and its 
apoptotic effects210. Also, mitochondrial CypD knockdown is associated with STAT3 
activation which leads to an increase in cell proliferation, by accelerating entry into S-phase, 
and migration, via the chemokine network, CXCL12-CXCR4211. Both of these phenotypes are 
closely linked to cancer progression and metastasis. Furthermore, CypD-/- mice exhibit similar 
phenotype to Pin1-/- mice in terms of abnormalities observed in retina and breast development 
which could potentially lead to malignant transformations in these organs212,213. Also, 
transcriptional and posttranslational regulation of CypD by Pin1 was demonstrated in the more 
recent study therefore explaining the phenotypical similarities observed in CypD-/- and Pin1-/- 
mice213. 
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Pin1 has been researched extensively for its oncogenic role in cancer214. Pin1 is also important 
for tumourigenesis and for the regulation of CSCs via the Notch pathway215 . In fact, deletion 
of Pin1 in mice prevented oncogenic activation of Neu and Ha-Ras which abrogated breast 
cancer216. In p53-KO mice Pin1 deletion was able to completely abrogate tumour development 
but had adverse effects including thymic hyperplasia mediated via the Notch pathways217. 
Nevertheless, Pin1 does not affect the p53 tumour suppressor activity218. Other cancer-
associated processes that Pin1 affects include regulation of cell cycle, DNA damage, cell 
signaling, transcription and splicing219. In terms of cell-cycle regulation, Pin1 also has a role in 
cytokinesis by binding to the crucial centrosome protein, Cep55, which further explains its role 
in tumourigenesis220 
 
PPIases as targets to prevent ageing or to treat age-related diseases 
An advantage of characterising this gene family is that they are targetable and various drugs 
targeting these proteins have been reported, including FK506, sirolimus/rapamycin, 
cyclosporine, and tacrolimus22. Ligands of these proteins, although first approved as 
immunosuppressive agents, for the prevention of allograft rejection, are effective against age-
related diseases. Several FKBP-binding macrocyclic drugs, everolimus, zotarolimus and 
temsirolius are in phase III trials as targets for cell proliferation, immunosuppression and anti-
cancer effects23. Recent evidence has also identified rapamycin/sirolimus as being the first drug 
to extend lifespan in a range of species from yeast to mammals221,222, highlighting the potential 
for drug targeting within this gene family to alleviate the ageing process. Importantly, recent 
studies have also shown that FK506-binding proteins can modulate Akt-mTOR signalling in 
the absence of rapamycin21. 
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One of the problems associated with PPIase inhibitors however, is their off-target effects, 
particularly and not surprisingly, immunosuppression. However, more recently there has been 
a concerted effort to generate compounds that lack immunosuppressive activity, with various 
levels of success. Examples of such compounds include non-immunosuppressive analogues of 
cyclosporine A which may have applications in multiple therapeutic areas e.g. Alisporivir 
(Debio 025) and NIM811223,224. Similarly, the development of cell impermeable, non-
immunosuppressive analogues of cyclosporine A has permitted the inhibition of extracellular 
CypA in mouse models of inflammation225. Such drugs have huge potential in the treatment of 
ageing disease in which CypA is involved.  
 
The novel FKBPL-based therapeutic, ALM201, unlike other PPIases, appears to be protective 
of age-related diseases147,154,187,193,194,196; ALM201 is a peptide mimetic of FKBPL and could 
essentially correct a deficiency in FKBPL in a number of diseases. It has already completed 
preclinical evaluation for imminent phase I/II clinical trials in cancer patients196; our 
unpublished data also suggests that it has activity against a number of other inflammatory 
conditions.  
 
Conclusion 
In conclusion, there are many different significant roles of PPIases in age-related processes and 
diseases as indicated above (Table 1; Figure 2). Even though these proteins belong to the same 
family group, their roles are quite diverse and in some instances opposite. Therefore, it is of a 
paramount importance to elucidate the mechanisms involved in the interactive regulation of 
this gene family. This may allow the development of a genetic signature which could stratify 
patients with higher predisposition to unhealthy aging therefore enabling early treatment to 
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delay or prevent these age-related vascular diseases and their complications. Members of this 
family of proteins are therefore excellent targets for interventions as well as biomarkers of 
aging and age-related diseases. Because many of the PPIase family members are secreted226,227, 
monitoring them within ageing populations will be minimally invasive and therefore practical 
for routine clinical use or home test. 
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Figure 1. Different mechanisms involved in aging and the associated targeting strategies. ME – microenvironment; 
NAD ‐ nicotaminamide adenine dinucleotide (the sirtuin pathway activator).
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Figure 2. PPIases in aging and age‐related diseases (cancer, cardiovascular disease and chronic kidney disease).
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Table 1: Summary of the roles of PPIases in the age-related diseases. ROS – reactive oxygen species; ACS – acute coronary syndrome; MEK 
- mitogen activated protein kinase; mPTP - mitochondrial permeability transition pore; APP – amyloid precursor protein; T2D – type II diabetes; 
RyRs - ryanodine receptors; AR-androgen receptor; HIF-1α – hypoxia inducible factor 1 α; ER – oestrogen receptor; CSCs – cancer stem cells 
